Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
63.74 INR | +4.18% | +16.68% | +70.25% |
Valuation
Fiscal Period: März | 2020 | 2021 | 2022 | 2023 |
---|---|---|---|---|
Capitalization 1 | 26.45 | 72.09 | 75.6 | 66.44 |
Enterprise Value (EV) 1 | 40.86 | 87.44 | 75.57 | 66.02 |
P/E ratio | 9.21 x | -12.9 x | -825 x | 10.3 x |
Yield | - | - | - | - |
Capitalization / Revenue | 3.12 x | 34.6 x | 107 x | 2.44 x |
EV / Revenue | 4.83 x | 42 x | 107 x | 2.43 x |
EV / EBITDA | 7.27 x | -65.2 x | -20.3 x | 7.51 x |
EV / FCF | 10.6 x | -6.31 x | -4.05 x | -38.8 x |
FCF Yield | 9.4% | -15.9% | -24.7% | -2.58% |
Price to Book | 0.52 x | 1.61 x | 2.63 x | 1.88 x |
Nbr of stocks (in thousands) | 3,055 | 3,055 | 3,055 | 3,055 |
Reference price 2 | 8.660 | 23.60 | 24.75 | 21.75 |
Announcement Date | 20-12-07 | 21-12-07 | 22-12-06 | 23-09-07 |
Income Statement Evolution (Annual data)
Fiscal Period: März | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
---|---|---|---|---|---|---|
Net sales 1 | 5.944 | 9.85 | 8.466 | 2.081 | 0.7056 | 27.23 |
EBITDA 1 | 1.039 | 4.276 | 5.62 | -1.341 | -3.721 | 8.788 |
EBIT 1 | 0.2813 | 2.339 | 3.834 | -3.233 | -4.564 | 8.709 |
Operating Margin | 4.73% | 23.74% | 45.29% | -155.37% | -646.85% | 31.99% |
Earnings before Tax (EBT) 1 | 0.5859 | 2.347 | 2.057 | -5.018 | -0.0165 | 6.489 |
Net income 1 | 0.3409 | 2.325 | 2.86 | -5.591 | -0.0934 | 6.483 |
Net margin | 5.73% | 23.6% | 33.78% | -268.67% | -13.24% | 23.81% |
EPS 2 | 0.1100 | 0.7600 | 0.9400 | -1.830 | -0.0300 | 2.120 |
Free Cash Flow 1 | -1.672 | -11.2 | 3.842 | -13.86 | -18.67 | -1.701 |
FCF margin | -28.13% | -113.67% | 45.38% | -666.29% | -2,646.16% | -6.25% |
FCF Conversion (EBITDA) | - | - | 68.36% | - | - | - |
FCF Conversion (Net income) | - | - | 134.33% | - | - | - |
Dividend per Share | - | - | - | - | - | - |
Announcement Date | 18-09-04 | 19-07-31 | 20-12-07 | 21-12-07 | 22-12-06 | 23-09-07 |
Balance Sheet Analysis
Fiscal Period: März | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
---|---|---|---|---|---|---|
Net Debt 1 | 7.39 | 14 | 14.4 | 15.4 | - | - |
Net Cash position 1 | - | - | - | - | 0.03 | 0.41 |
Leverage (Debt/EBITDA) | 7.113 x | 3.283 x | 2.564 x | -11.45 x | - | - |
Free Cash Flow 1 | -1.67 | -11.2 | 3.84 | -13.9 | -18.7 | -1.7 |
ROE (net income / shareholders' equity) | 0.76% | 5.01% | 5.83% | -11.7% | -0.25% | 20.2% |
ROA (Net income/ Total Assets) | 0.28% | 2.11% | 3.16% | -2.59% | -5% | 13.2% |
Assets 1 | 123.2 | 110.2 | 90.6 | 216.2 | 1.869 | 48.94 |
Book Value Per Share 2 | 14.80 | 15.60 | 16.50 | 14.70 | 9.420 | 11.50 |
Cash Flow per Share 2 | 0.0100 | 0.2500 | 0.1200 | 0.0400 | 0.0100 | 0.1400 |
Capex 1 | 9.43 | - | 4.77 | 15.8 | - | - |
Capex / Sales | 158.59% | - | 56.33% | 758.99% | - | - |
Announcement Date | 18-09-04 | 19-07-31 | 20-12-07 | 21-12-07 | 22-12-06 | 23-09-07 |
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
- Stock Market
- Equities
- GVBL6 Stock
- Financials Genomic Valley Biotech Limited